In a pregnant patient on low‑dose aspirin and prophylactic enoxaparin who had a subchorionic hemorrhage identified at 6 weeks gestation but it is no longer visualized on subsequent ultrasounds, what is the most likely source of the bleeding and how should the anticoagulant therapy be managed?

Most Likely Source of Bleeding and Anticoagulant Management

The subchorionic hemorrhage identified at 6 weeks was most likely caused by the low-dose aspirin, and since it has resolved on subsequent ultrasounds, you should continue both the aspirin and prophylactic enoxaparin as originally indicated. 1

Understanding the Source of Bleeding

Low-dose aspirin is strongly associated with first-trimester subchorionic hemorrhages. Research demonstrates that aspirin increases SCH occurrence almost four-fold compared to patients not taking aspirin (40.2% vs 10.9% in general obstetric populations), regardless of fertility diagnosis or treatment method 1. This association is independent of heparin use, which does not appear to affect SCH frequency in the first trimester 1.

The mechanism relates to aspirin's antiplatelet effects during early placental implantation and formation, when the chorionic membrane is separating from the uterine wall. While enoxaparin can also cause subchorionic hematomas 2, the timing at 6 weeks and the research evidence make aspirin the more likely culprit in your patient.

Clinical Significance of Resolution

The key prognostic factor is that the SCH has resolved. First-trimester SCH outcomes correlate with:

• Size of the hematoma (both relative and absolute) 3
• Changes on follow-up examination 3
• Severity of associated vaginal bleeding 3

Since your patient's SCH is no longer visualized, this represents favorable evolution. The concerning scenarios would be persistent or enlarging hematomas, particularly those exceeding 25-30% of the gestational sac size 4.

Anticoagulant Management Decision

Continue both medications at their current doses based on the following reasoning:

For Prophylactic Enoxaparin:

The ASH 2018 guidelines support standard-dose LMWH prophylaxis during the antepartum period for women with appropriate indications 5. The guidelines acknowledge very low certainty evidence but provide conditional recommendations for prophylaxis in women with clinical risk factors 5. Since your patient was already deemed to require prophylactic anticoagulation, the resolved SCH does not change this underlying indication.

Enoxaparin is the preferred anticoagulant throughout pregnancy over vitamin K antagonists 6, and the guidelines recommend continuing LMWH during all trimesters 6.

For Low-Dose Aspirin:

While aspirin does increase bleeding risks—including SCH 1, placental abruption (number needed to harm: 287), and postpartum hemorrhage (number needed to harm: 79) 7—the FDA labeling notes particular concern only during the last 3 months of pregnancy unless directed by a physician 8.

The critical clinical decision point: Was there a valid indication for aspirin initially? If aspirin was prescribed for preeclampsia prevention or another vascular indication, the benefits of continuing typically outweigh the risks, especially now that the SCH has resolved.

Monitoring Strategy Going Forward

• Serial ultrasounds to confirm continued resolution of the SCH
• Watch for recurrent bleeding or new hematoma formation
• If SCH recurs and exceeds 25-30% of gestational sac size, reassess the risk-benefit ratio 4
• Monitor for other pregnancy complications associated with resolved first-trimester SCH: premature rupture of membranes (13.5% vs 3.8%) and miscarriage risk (14.4% vs 6.4%) 9
• Consider checking for autoimmune abnormalities (lupus anticoagulant, anticardiolipin antibody, antinuclear antibodies) if not already done, as these increase miscarriage risk in SCH patients (28.2% vs 7.6%) 9

Common Pitfalls to Avoid

Do not discontinue anticoagulation based solely on a resolved first-trimester SCH. The original indication for prophylactic enoxaparin (likely history of VTE or high-risk thrombophilia) remains valid throughout pregnancy. Stopping anticoagulation could expose the patient to life-threatening thromboembolism.

Do not assume all first-trimester bleeding requires stopping aspirin. The resolution of the SCH indicates the bleeding source has healed. If aspirin was indicated for preeclampsia prevention in a high-risk patient, discontinuing it increases the risk of a far more serious complication.